Abstract
Objective
Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4.
Methods
In a randomized, two-phase crossover study, 10 healthy volunteers were pretreated for 2 days with either 600 mg oral gemfibrozil or placebo twice daily. On day 3, they received a single dose of 600 mg gemfibrozil or placebo, and 1 h later they received a single oral dose of 30 mg pioglitazone. Plasma concentrations of pioglitazone and both active metabolites M-III and M-IV were measured for up to 120 h.
Results
Gemfibrozil raised the mean total area under the concentration-time curve (AUC) of parent pioglitazone 3.4-fold (P<0.001). No statistically significant changes were seen in the total AUC of M-III or M-IV after gemfibrozil pretreatment. Gemfibrozil reduced the M-III/pioglitazone and M-IV/pioglitazone AUC0–∞ ratio by 71% (P<0.001) and 65%(P<0.001), strikingly prolonging their t½.
Conclusion
Gemfibrozil greatly increased the plasma concentration of parent pioglitazone and also inhibited the further metabolism of M-III and M-IV. Careful blood glucose monitoring and dosage adjustments are suggested during coadministration of pioglitazone and gemfibrozil.
Similar content being viewed by others
References
Füchtenbusch M, Standl E, Schatz H (2000) Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108:151–163
Kiyota Y, Kondo T, Maeshiba Y (1997) Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 47:22–28
Tanis SP, Parker TT (1996) Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent Pioglitazone. J Med Chem 39:5053–5063
Hiraga K (1997) Clinical phase 1 study of AD-4833: single-dose and repeated-dose studies. Jpn J Clin Exp Med 74:1184–1201
Niemi M, Backman JT, Granfors M, Laitila J (2003) Gemfibrozil considerably increases the plasma concentration of rosiglitazone. Diabetologia 46:1319–1323
Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685–691
Deng LJ, Wang F, Xie HZ, Li HD (2005) Simultaneous determination of pioglitazone and its two active metabolites in human plasma by HPLC-MS. Chin Pharm J 40:616–620
Diletti E, Hauschke D, Steinijans VW (1991) Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29:1–8
Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29:323–328
Eckland DA, Danhof M (2002) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol 108:s234–s242
Sahi J, Black CB, Hamilton GA (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439–446
Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359–1361
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347–351
Prueksaritanont T, Richards KM, Qiu Y (2005) Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22:71–78
Niemi M, Pertti J, Kari T (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 70:439–451
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deng, LJ., Wang, F. & Li, HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 61, 831–836 (2005). https://doi.org/10.1007/s00228-005-0042-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0042-6